WallStSmart

Boston Scientific Corp (BSX)vsCapsoVision, Inc. Common Stock (CV)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 151254% more annual revenue ($21.07B vs $13.92M). BSX leads profitability with a 16.6% profit margin vs -210.1%. BSX earns a higher WallStSmart Score of 60/100 (C+).

BSX

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.78

CV

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -13.46
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-13.3%)

Margin of Safety

-13.3%

Fair Value

$39.14

Current Price

$43.70

$4.56 premium

UndervaluedFair: $39.14Overvalued

Intrinsic value data unavailable for CV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX3 strengths · Avg: 8.3/10
Market CapQuality
$64.07B9/10

Large-cap with strong market position

PEG RatioValuation
0.768/10

Growing faster than its price suggests

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

CV1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Areas to Watch

BSX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

EPS GrowthGrowth
-21.5%2/10

Earnings declined 21.5%

CV4 concerns · Avg: 3.8/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$323.27M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 16.6% and operating margin at 19.6%. PEG of 0.76 suggests the stock is reasonably priced for its growth.

Bull Case : CV

The strongest argument for CV centers on Debt/Equity.

Bear Case : BSX

The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.

Bear Case : CV

The primary concerns for CV are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a value stock while CV is a turnaround play — different risk/reward profiles.

BSX is growing revenue faster at 1.4% — sustainability is the question.

BSX generates stronger free cash flow (868M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (60/100 vs 14/100), backed by strong 16.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

CapsoVision, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.

Visit Website →

Want to dig deeper into these stocks?